BSEM — BioStem Technologies Share Price
Last trade - 00:00- $29.32m
- $23.35m
- $47.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.06 | ||
| Price to Tang. Book | 6.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.55% | ||
| Return on Equity | -74.74% | ||
| Operating Margin | -65.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.52 | 4.34 | 16.69 | 69.66 | 47.48 | 28.74 | 53.93 | 170.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The Company's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. It also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.
Directors
- Marc Barhonovich CEO (42)
- Leon Willis CFO (70)
- Dave Woynarowski OTH
- Jennie Sandqvist DRC
- Andrew VanVurst DRC
- Henry VanVurst DRC
- Steven Velte DRC (43)
- Robert Watson DRC
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- February 12th, 2009
- Public Since
- July 11th, 2001
- No. of Shareholders
- 293
- No. of Employees
- 67
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,672,125
- Address
- 2836 Center Port Cir, POMPANO BEACH, 33064
- Web
- https://www.biostemtechnologies.com/
- Phone
- +1 9543808342
- Auditors
- KPMG LLP
Latest News for BSEM
Upcoming Events for BSEM
Q3 2026 Biostem Technologies Inc Earnings Release
Q4 2026 Biostem Technologies Inc Earnings Release
Similar to BSEM
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
As of Today at 19:37 UTC, shares in BioStem Technologies are trading at $1.57. This share price information is delayed by 15 minutes.
Shares in BioStem Technologies last closed at $1.57 and the price had moved by -67.66% over the past 365 days. In terms of relative price strength the BioStem Technologies share price has underperformed the S&P500 Index by -71.19% over the past year.
The overall consensus recommendation for BioStem Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBioStem Technologies does not currently pay a dividend.
BioStem Technologies does not currently pay a dividend.
BioStem Technologies does not currently pay a dividend.
To buy shares in BioStem Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.57, shares in BioStem Technologies had a market capitalisation of $29.32m.
Here are the trading details for BioStem Technologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BSEM
Based on an overall assessment of its quality, value and momentum BioStem Technologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioStem Technologies is $7.00. That is 345.86% above the last closing price of $1.57.
Analysts covering BioStem Technologies currently have a consensus Earnings Per Share (EPS) forecast of -$1.90 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioStem Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -69.41%.
As of the last closing price of $1.57, shares in BioStem Technologies were trading -63.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioStem Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioStem Technologies' management team is headed by:
- Marc Barhonovich - CEO
- Leon Willis - CFO
- Dave Woynarowski - OTH
- Jennie Sandqvist - DRC
- Andrew VanVurst - DRC
- Henry VanVurst - DRC
- Steven Velte - DRC
- Robert Watson - DRC